Acurx Pharmaceuticals Llc ((ACXP)) has held its Q3 earnings call. Read on for the main highlights of the call.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Acurx Pharmaceuticals’ recent earnings call highlighted a blend of positive strides and ongoing financial hurdles. The company celebrated achievements such as regaining NASDAQ compliance, expanding its patent portfolio, and making significant scientific presentations. However, the call also underscored financial challenges, including a net loss and reduced R&D spending, which remain areas of concern.
NASDAQ Compliance Achieved
Acurx Pharmaceuticals successfully regained compliance with NASDAQ listing rules by implementing a 1-for-20 reverse stock split. This strategic move ensured the company met the minimum bid price of $1 per share and maintained a stockholder equity threshold of $2.5 million, securing its position on the exchange.
Patent Expansion
The company strengthened its intellectual property portfolio with a new patent granted by the Australian Patent Office for DNA polymerase 3C inhibitors. This addition complements existing patents in the U.S., Israel, Japan, and India, bolstering the ACX-375C program’s global reach.
Successful Presentation at ID Week
Acurx was selected to present at ID Week in Atlanta, where it showcased ibezapolstat’s microbiome-sparing properties and new colonic microbiome data. This presentation highlighted the drug’s low probability of increasing infection risk, marking a significant step in its development.
Publication in Nature Communications
In collaboration with Leiden University Medical Center, Acurx published research in Nature Communications. This publication detailed structural biology research on ibezapolstat, representing a milestone in scientific collaboration and enhancing the drug’s development profile.
Financial Position Improvement
The company reported an improved financial position, ending the quarter with $5.9 million in cash, up from $3.7 million at the end of 2024. This improvement was supported by additional funds raised through warrant exercises and an equity line of credit.
Decrease in R&D Expenses
Acurx significantly reduced its research and development expenses from $1.2 million in Q3 2024 to $0.4 million in Q3 2025. This reduction was primarily due to decreased manufacturing and consulting costs, reflecting a strategic shift in resource allocation.
Net Loss Reduction
The company reported a net loss of $2 million for Q3 2025, a decrease from $2.8 million in Q3 2024. While this reduction indicates some financial improvement, it also highlights the ongoing challenges Acurx faces in achieving profitability.
Forward-Looking Guidance
Acurx Pharmaceuticals provided forward-looking guidance, emphasizing its strategic focus on financial stability and scientific advancement. The company plans to continue seeking funding opportunities for a phase three clinical trial of ibezapolstat, while maintaining its improved cash position and managing expenses effectively.
In summary, Acurx Pharmaceuticals’ earnings call painted a picture of a company making strategic advancements amid financial challenges. The positive sentiment surrounding NASDAQ compliance, patent expansion, and scientific achievements was tempered by the reality of reduced R&D spending and ongoing net losses. Investors will be keenly watching how Acurx navigates these challenges while pursuing future growth opportunities.